{"nctId":"NCT01410448","briefTitle":"Everolimus in de Novo Kidney Transplant Recipients","startDateStruct":{"date":"2011-11"},"conditions":["Kidney Transplantation"],"count":383,"armGroups":[{"label":"Immediate Everolimus (IE)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Everolimus","Drug: Cyclosporine","Drug: Steroids"]},{"label":"Delayed Everolimus","type":"EXPERIMENTAL","interventionNames":["Drug: Everolimus","Drug: Mycophenolate sodium","Drug: Cyclosporine","Drug: Steroids"]}],"interventions":[{"name":"Everolimus","otherNames":["Certican®"]},{"name":"Mycophenolate sodium","otherNames":["Myfortic®"]},{"name":"Cyclosporine","otherNames":["Neoral®"]},{"name":"Steroids","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion criteria:\n\n* Patients who are willing and able to participate in the study and who provide written informed consent before performing any study related procedure;\n* Men or women ≥18 years at transplant;\n* Recipients of 1st or 2nd single kidney transplant from deceased donor or living unrelated/related donor \\> 14 years;\n\nKey Exclusion criteria:\n\n* Patients who are recipients of multiple organs transplant, including two kidneys;\n* Historical or current peak PRA \\> 50%. Patients with already existing antibodies against the donor;\n* Thrombocytopenia (platelets \\< 75,000/mm³), absolute neutrophil count \\<1,500/mm³, leucopenia (leucocytes \\< 2,500/mm³) or hemoglobin \\< 7 g/dL;\n* Body mass index (BMI) \\> 30 Kg/m2;","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Without Wound Healing Complications - Worst-case Scenario","description":"The percentage of participants without wound healing complications was assessed. Wound healing complications consisted of lymphorrhea, fluid collections, wound dehiscence, wound infections and incisional hernia. In the worst-case scenario, failure, i.e. at least one healing complication occurrence, was identified in one of the following cases: wound complication occurrence, missing information about wound complication occurrence, or study discontinuation due to any reason.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.39","spread":null},{"groupId":"OG001","value":"61.58","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Without Wound Healing Complications - Worst-case Scenario","description":"The percentage of participants without wound healing complications was assessed. Wound healing complications consisted of lymphorrhea, fluid collections, wound dehiscence, wound infections and incisional hernia. In the worst-case scenario, failure, i.e. at least one healing complication occurrence, was identified in one of the following cases: wound complication occurrence, missing information about wound complication occurrence or study discontinuation due to any reason for participants who did not complete the 12 month follow-up visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.80","spread":null},{"groupId":"OG001","value":"59.47","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Experienced Treatment Failure - Worst-case Scenario","description":"The percentage of participants who experienced treatment failure was assessed. Treatment failure was defined as the occurrence of at least one failure event among death, graft loss or biopsy-proven acute rejection (BPAR). In the worst-case scenario, treatment failure was identified in one of the following cases: occurrence of at least one treatment failure event or study discontinuation due to any reason.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.40","spread":null},{"groupId":"OG001","value":"21.05","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient Survival Rate: Percentage of Deaths - Worst-case Scenario","description":"The percentage of deaths was assessed. In the worst-case scenario, failure, i.e. death, was identified in one of the following cases: participant's death or study discontinuation due to any reason.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.22","spread":null},{"groupId":"OG001","value":"18.42","spread":null}]}]}]},{"type":"SECONDARY","title":"Participant/Graft Survival Rate: Percentage of Participants With Failure Events of Death or Graft Loss - Worst-case Scenario","description":"The percentage of participants who experienced death or graft loss was assessed. In the worst-case scenario, failure, i.e. participants death or graft loss, was identified in one of the following cases: occurrence of at least one failure event or study discontinuation due to any reason.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.74","spread":null},{"groupId":"OG001","value":"18.42","spread":null}]}]}]},{"type":"SECONDARY","title":"Graft Survival Rate: Percentage of Participants With Graft Loss - Worst-case Scenario","description":"The percentage of participants who experienced graft loss was assessed. In the worst-case scenario, failure, i.e. graft loss, was identified in one of the following cases: occurrence of graft loss or discontinuation due to any reason.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.74","spread":null},{"groupId":"OG001","value":"18.42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.25","spread":null},{"groupId":"OG001","value":"19.47","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With BPAR - Worst-case Scenario","description":"A biopsy-proven acute rejection was defined as a biopsy graded IA, IB, IIA, IIB or III. In the worst-case scenario, failure, i.e. BPAR, was identified in one of the following cases: occurrence of BPAR or study discontinuation due to any reason.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.40","spread":null},{"groupId":"OG001","value":"21.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.54","spread":null},{"groupId":"OG001","value":"24.74","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Delayed Graft Function (DGF) -","description":"DGF was defined as the need for dialysis in the first week after transplant, excluding Renal Replacement Therapy within the first 24 hours after transplantation.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.83","spread":null},{"groupId":"OG001","value":"31.58","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of DGF","description":"The duration of DGF was defined as the elapsed time from first to last day of post-transplant dialysis.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.50","spread":null},{"groupId":"OG001","value":"5.50","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) (Calculated With Modified Diet in Renal Disease (MDRD)-4 Formula - ITT","description":"Renal function was assessed by measuring serum creatinine and serum urea and by calculating creatinine clearance using the MDRD-4 formula. eGFR = 186.3\\*(serum creatinine \\[mg/dL\\])\\^-1.154 \\* (age at screening) -0.203 \\* (0.742 if female) \\* (1.21 if African American). A positive change from baseline indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.64","spread":"22.45"},{"groupId":"OG001","value":"39.13","spread":"21.46"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) (Calculated With Modified Diet in Renal Disease (MDRD)-4 Formula - Modified ITT","description":"Renal function was assessed by measuring serum creatinine and serum urea and by calculating creatinine clearance using the MDRD-4 formula. eGFR = 186.3\\*(serum creatinine \\[mg/dL\\])\\^-1.154 \\* (age at screening) -0.203 \\* (0.742 if female) \\* (1.21 if African American). A positive change from baseline indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.26","spread":"18.69"},{"groupId":"OG001","value":"41.56","spread":"19.90"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum Creatinine - ITT","description":"Blood samples were collected to assess serum creatinine measurements. A negative change from baseline indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.79","spread":"2.74"},{"groupId":"OG001","value":"-5.13","spread":"2.32"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum Creatinine - Modified ITT","description":"Blood samples were collected to assess serum creatinine measurements. A negative change from baseline indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.96","spread":"2.48"},{"groupId":"OG001","value":"-5.22","spread":"2.24"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Proteinuria","description":"Incidence of proteinuria (\\>1,000 mg/day in urine collected in 24 hours or \\> 1.0 if measured on the urine protein/creatinine concentration ratio in a spot urine sample) was assessed.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.15","spread":null},{"groupId":"OG001","value":"4.21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.91","spread":null},{"groupId":"OG001","value":"68.42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.94","spread":null},{"groupId":"OG001","value":"27.37","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Acute Rejection (AR)","description":"AR was defined as an episode of increased serum creatinine \\>30% that was clinically diagnosed as an acute rejection but was not biopsy proven.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.44","spread":null},{"groupId":"OG001","value":"10.53","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a New Onset of Malignancy","description":"The percentage of participants with a new onset of malignancy was assessed.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.68","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a New Onset of Diabetes","description":"The percentage of participants with a new onset of diabetes was assessed.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.14","spread":null},{"groupId":"OG001","value":"4.05","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":73,"n":193},"commonTop":["Anaemia","Urinary tract infection","Hypertension","Lymphocele","Hypocalcaemia"]}}}